

REMARKS

Claims 6-9, 11-13, 15, 17, 19,-21, 25, 28, 31, and 54-56 have been amended and claim 51 has been cancelled without prejudice. These amendments are non-substantive, i.e. the amendments are made merely to address matters of form.

Claims 7-18, 20, 21, 25-46 and 52 were objected to under 37 CFR 1.75(c).

It is believed the amendments made herein obviate this formal-type objection.

Applicant respectfully requests reconsideration of the Restriction Requirement on the grounds that consideration and examination of the several groups specified in the Restriction should not impose an undue burden. Additionally, significant expense and time would be saved if multiple groups were searched and examined at this time.

Reconsideration of the Restriction Requirement at this time is earnestly solicited.

Nevertheless, to provide a complete response to the Restriction Requirement, Applicants elect Group I, as that group is defined in the Office Action. As indicated in the Office Action, claims within that group include claims 1, 2, 3, 6, 8, 9, 11, 12, 15-19, 21, 31-40, 41-46 and 53-66.

At pages 4, 12 and 13 of the Office Action, a species election is requested. In response, Applicants elect a compound of Formula IIIA and the third compound of the right column of Table 1 on page 35 of the application.

At page 12, paragraph 11 of the Office Action, a further species election is requested. In response, Applicants elect “A drug discovery process where the metal ion binding site is introduced at or in the vicinity of 1) a site where the binding of the test compound will interference with the binding to another protein”.

At page 13, paragraph 12 of the Office Action, a further species election is requested. In response, Applicants elect “A drug discovery process where binding is determined using changes in the biological activity of the protein”.

At page 13, paragraph 13 of the Office Action, a further species election is requested. In response, Applicants elect protein.

At page 14, paragraph 14 of the Office Action, a further species election is requested. In response, Applicants elect membrane receptor.

At page 14, paragraph 15 of the Office Action, a further species election is requested. In response, Applicants elect 7TM receptor.

At pages 14-15, paragraph 16 of the Office Action, a further species election is requested. In response, Applicants elect 3 to about 8.

At page 15, paragraph 17 of the Office Action, a further species election is requested. In response, Applicants elect Cu.

At page 15, paragraph 18 of the Office Action, a further species election is requested. In response, Applicants elect N and S.

At pages 15-16, paragraph 19 of the Office Action, a further species election is requested. In response, Applicants elect a compound of Formula IIIA and the third compound of the right column of Table 1 on page 35 of the application.

At page 16, paragraph 20 of the Office Action, a further species election is requested. In response, Applicants elect a nitrogen residue.

At page 16, paragraph 21 of the Office Action, a further species election is requested. In response, Applicants elect His.

At page 17, paragraph 22 of the Office Action, a further species election is requested. In response, Applicants elect Cu.

At page 17, paragraph 23 of the Office Action, a further species election is requested. In response, Applicants elect metal ion-phenanthroline.

At page 17, paragraph 24 of the Office Action, a further species election is requested. In response, Applicants elect a compound of Formula IIIA and the third compound of the right column of Table 1 on page 35 of the application.

At page 19, paragraph 25 of the Office Action, a further species election is requested. In response, Applicants elect Cu.

At page 20, paragraph 26 of the Office Action, a further species election is requested. In response, Applicants elect Cu.

At page 21, paragraph 27 of the Office Action, a further species election is requested. In response, Applicants elect a molecular weight that is at most 2000; the log P is at most 7; the number of hydrogen bonds is at most 10; and the number of hydrogen acceptors is at most 15.

The election of Group I is being made solely to comply with the Restriction Requirement and the right to file divisional applications on non-elected subject matter is reserved.

Applicants further respectfully request that rejoinder of the IV groups be considered by the Examiner following the search.

Early consideration and allowance of the application are earnestly solicited.

Respectfully submitted,



Peter F. Corless (Reg. 33,860)
EDWARDS & ANGELL, LLP
P.O. Box 55874
Boston, MA 02205
Telephone: 617-439-4444
Facsimile: 617-439-4170

Customer No.: 21874